Evidence of androgen action in endometrial and ovarian cancers
The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Abstract
Endometrial cancer (EC) and ovarian cancer are common gynaecological malignancies. The impact of androgen action in these cancers is poorly understood; however, there is emerging evidence to suggest that targeting androgen signalling may be of therapeutic benefit. Epidemiological evidence suggests that there is an increased risk of EC associated with exposure to elevated levels of androgens, and genetic variants in genes related to both androgen biosynthesis and action are associated with an increased risk of both EC and ovarian cancer. Androgen receptors (ARs) may be a potential therapeutic target in EC due to reported anti-proliferative activities of androgens. By contrast, androgens may promote growth of some ovarian cancers and anti-androgen therapy has been proposed. Introduction of new therapies targeting ARs expressed in EC or ovarian cancer will require a much greater understanding of the impacts of cell context-specific AR-dependent signalling and how ARs can crosstalk with other steroid receptors during progression of disease. This review considers the evidence that androgens may be important in the aetiology of EC and ovarian cancer with discussion of evidence for androgen action in normal and malignant endometrial and ovarian tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparison between the patterns of expression of receptor proteins in normal endometrium with samples of endometrial cancer and endometriosis lesions has revealed evidence of aberrant expression of both AR and ERs, which may result in novel disease-specific targets for the action of steroids generated by intracrine activation/metabolism discussed below.”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
In the citing paper
“We and others have shown that AR are widely expressed in EC and also in EC cell lines such as Ishikawa, which have been extensively studied (reviewed in [26]).”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
In the citing paper
“We and others have shown that AR are widely expressed in EC and also in EC cell lines such as Ishikawa, which have been extensively studied (reviewed in [26]).”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [26]
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293 · cited 2×
“In the UK, it is the fifth most common female cancer (http://www.cancerresearchuk.org/) consistent with higher incidence in high-resource countries (Ferlay et al. 2010).”
BackgroundIntegrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784 · cited 1×
“One of the most studied polymorphisms of the AR NTD is the CAG-repeat sequence encoding poly-glutamine repeats (Spada et al. 1991).”
BackgroundTHE JOURNAL OF REPRODUCTIVE MEDICINE: PATIENT ANXIETY DURING GYNECOLOGIC EXAMINATIONS
Reddy, D. M., & Wasserman, S. A. (1999) · American Journal of Nursing · doi:10.1097/00000446-199901000-00024 · Cited by 2,483
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364 · cited 1×
“According to a recent report from FIGO, ovarian cancer is the seventh most common cancer in women worldwide (Prat 2013).”
BackgroundChamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,156 · cited 1×
“The length of the CAG-repeat region correlates inversely with AR transactivation capability (Chamberlain et al. 1994).”
BackgroundMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Research works printed but not linked: 9
- 2008, NUCLEAR RECEPTOR SIGNALING, 6, 008e
- Horie, 1992, Human Reproduction, 7, 184, 10.1093/humrep/ · doi:10.1093/humrep/
- Li, 2003, Clinical Cancer Research, 9, 3667
- 2011, JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 16, 999
- 1996, HUMAN CELL, 9, 109
- 2013, INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS, 124, 1
- Rabban, 2005, The Journal of reproductive medicine, 50, 467
- Syed, 2001, Cancer Research, 61, 6768
- 2013, EMBO MOLECULAR MEDICINE, 5, 983
Cited by
Wang, Y.-X., Arvizu, M., Rich-Edwards, J. W., Stuart, J. J., Manson, J. E., Missmer, S. A., Pan, A., & Chavarro, J. E. (2020) · BMJ · doi:10.1136/bmj.m3464 · Cited by 178
Wiwatpanit, T., Murphy, A. R., Lu, Z., Urbanek, M., Burdette, J. E., Woodruff, T. K., & Kim, J. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz100 · Cited by 135
Androgens and endometrium: new insights and new targets
Simitsidellis, I., Saunders, P. T. K., & Gibson, D. A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.022 · Cited by 107
Self-citationEpidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences
Felix, A. S., Yang, H., Bell, D. W., & Sherman, M. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_1 · Cited by 107
SiRNA and epigenetic aberrations in ovarian cancer
Mirzaei, H., Yazdi, F., Salehi, R., & Mirzaei, H. R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.153661 · Cited by 106
Metadata
- Authors
- Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K.
- Affiliations
- MRC Centre for Reproductive Health (GB)
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-02-28
- Volume
- 21
- Issue
- 4
- Pages
- T203-T218
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2108865532
- Cited by
- 73
- References
- 154
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 11 · 2015: 4 · 2014: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- androgen action, endometrial cancer, ovarian cancer, androgen receptor, androgen signaling, androgen production, genetic variants, cancer risk, antiandrogen therapy, tumor progression, endometrium, ovary
- MeSH terms
- Androgen Antagonists, Androgens, Endometrium, Female, Humans, Ovarian Neoplasms, Ovary, Receptors, Androgen, Endometrial Neoplasms, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence of androgen action in endometrial and ovarian cancers. https://app.cochat.ai/papers/10.1530/erc-13-0551
- The paper
- Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014). Evidence of androgen action in endometrial and ovarian cancers. Endocrine-Related Cancer. https://doi.org/10.1530/erc-13-0551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.